Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
NCT03628612
Age 1 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to improve patient outcomes and potentially enhance the effectiveness of existing treatments. Here are some key details about the study:
- The study involves a unique combination of therapies that have not been widely tested together before.
- Patients will receive treatment in a clinical setting, which allows for close monitoring and support.
- The goal is to assess how well this combination works in managing the disease and improving patients' quality of life.
- Participants will be closely observed for any side effects and overall health improvements.
- This study aims to provide insights into how different treatment strategies can be combined to achieve better results.
Third Opinion AI Generated Synopsis
Trial Summary
Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.
Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
